-- 根据韩国交易所周四发布的公告,SK生物制药(KRX:326030)公布第一季度归属于股东的净利润为1052亿韩元,较去年同期的233亿韩元增长351%。 这家韩国生物制药公司的销售额同比增长58%,从1444亿韩元增至2279亿韩元。 SK生物制药的股价在近期的交易中上涨超过2%。
Related Articles
ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1
ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.
Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond
Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.
Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates
Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.